Innate Pharma (IPHA) Cash from Operations (2020 - 2025)
Innate Pharma (IPHA) reported Cash from Operations of 61409115.62 for Q4 2025, down 733.34% on a YoY basis from 9696072.28 in Q4 2024, and down 733.34% quarter-over-quarter from 7369033.88 in Q4 2024.
Innate Pharma (IPHA) Cash from Operations (2020 - 2025) Analysis & Trends
Innate Pharma has reported Cash from Operations for 6 years, with the latest figure at 61409115.62 in Q4 2025.
- For the quarter ending Q4 2025, Cash from Operations fell 733.34% year-over-year to 61409115.62; the trailing twelve-month figure through Dec 2025 stood at 116294195.15 (down 56.25% YoY), and the FY2025 full-year result was 61409115.62, down 733.34% from the prior year.
- Cash from Operations for Q4 2025 stood at 61409115.62, down from 7369033.88 in the prior quarter.
- The five-year high for Cash from Operations was 7369033.88 in Q4 2024, with the low at 66873109.89 in Q4 2021.
- Historically, Cash from Operations has averaged 34319664.26 across 5 years, with a median of 35031527.5 in 2023.
- Annual changes were most pronounced in 2024 — Cash from Operations jumped 78.96% — and 2025, when it slumped 733.34%.
- Innate Pharma's Cash from Operations stood at 66873109.89 in 2021, then soared by 70.78% to 19542838.28 in 2022, then slumped by 79.26% to 35031527.5 in 2023, then surged by 78.96% to 7369033.88 in 2024, then plunged by 733.34% to 61409115.62 in 2025.
- The last three Cash from Operations figures came in at 61409115.62 (Q4 2025), 7369033.88 (Q4 2024), and 35031527.5 (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Innate Pharma | 194.19 Mn | 194.19 Mn | - | -61.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -61.41 Mn |
| Dec 31, 2025 | -61.41 Mn |
| Dec 31, 2024 | -7.37 Mn |
| Dec 31, 2024 | -7.37 Mn |
| Dec 31, 2023 | -35.03 Mn |
| Dec 31, 2023 | -35.03 Mn |
| Jun 30, 2023 | -12.48 Mn |
| Jun 30, 2023 | -12.48 Mn |
| Dec 31, 2022 | -19.54 Mn |
| Dec 31, 2022 | -19.54 Mn |
| Dec 31, 2021 | -66.87 Mn |
| Dec 31, 2021 | -66.87 Mn |
| Jun 30, 2021 | -37.53 Mn |
| Jun 30, 2021 | -37.53 Mn |
| Dec 31, 2020 | -61.72 Mn |
| Dec 31, 2020 | -61.72 Mn |
| Jun 30, 2020 | -63.91 Mn |
| Jun 30, 2020 | -63.91 Mn |